CryoCell International Inc (CCEL)vsNovartis AG ADR (NVS)
CCEL
CryoCell International Inc
$4.15
0.00%
HEALTHCARE · Cap: $39.10M
NVS
Novartis AG ADR
$150.47
-0.50%
HEALTHCARE · Cap: $302.86B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 184193% more annual revenue ($57.36B vs $31.13M). NVS leads profitability with a 17.5% profit margin vs -6.3%. CCEL appears more attractively valued with a PEG of 1.34. NVS earns a higher WallStSmart Score of 48/100 (D+).
CCEL
Hold47
out of 100
Grade: D+
NVS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.5%
Fair Value
$5.02
Current Price
$4.15
$0.87 discount
Margin of Safety
-56.8%
Fair Value
$95.95
Current Price
$150.47
$54.52 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 129 in profit
Earnings expanding 75.1% YoY
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 34.0%
Every $100 of equity generates 27 in profit
Generating 4.8B in free cash flow
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
Operating margin of 0.6%
Distress zone — elevated risk
Premium valuation, high expectations priced in
4.7% revenue growth
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CCEL
The strongest argument for CCEL centers on Return on Equity, EPS Growth, Debt/Equity. PEG of 1.34 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.0%.
Bear Case : CCEL
The primary concerns for CCEL are Revenue Growth, Market Cap, Operating Margin.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
CCEL profiles as a turnaround stock while NVS is a value play — different risk/reward profiles.
CCEL carries more volatility with a beta of 0.55 — expect wider price swings.
NVS is growing revenue faster at 4.7% — sustainability is the question.
NVS generates stronger free cash flow (4.8B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (48/100 vs 47/100), backed by strong 17.5% margins. CCEL offers better value entry with a 33.5% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CryoCell International Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Cryo-Cell International, Inc. is dedicated to cell processing and cryogenic cell storage with a focus on collecting and preserving umbilical cord blood stem cells for family use. The company is headquartered in Oldsmar, Florida.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?